Clinical Trials Logo

Prosthetic Joint Infection clinical trials

View clinical trials related to Prosthetic Joint Infection.

Filter by:

NCT ID: NCT06062251 Recruiting - Clinical trials for Prosthetic Joint Infection

Assessing the Performance of Shotgun Metagenomics in the Diagnosis of Complex Prosthetic Joint Infections

METAGENOS
Start date: February 27, 2024
Phase:
Study type: Observational

The objectiveof this of a prospective, multicentre study is to evaluate the performance of shotgun metagenomics in the diagnosis of chronic Prosthetic joint infection (PJI) in comparison with the adapted MSIS diagnostic score.. The main questions it aims to answer are: - To evaluate the performance of shotgun metagenomics in the diagnosis of chronic PJI in comparison with culture. - To describe the epidemiology of bacterial species responsible for chronic PJI in Western France and their potential resistance to antibiotics. - Analyzing the diagnostic performance of shotgun culture and metagenomics as a function of potentially administered antibiotic treatments A total of 143 patients sampled will be included. Six intraoperative samples will be taken for each patient, as part of routine care. In addition to the standard preoperative check-up, an extra volume of blood will be taken for CRP measurement at inclusion.

NCT ID: NCT05676801 Recruiting - Clinical trials for Surgical Site Infection

Effect of Photodynamic Therapy on Skin Microbiome. Single Center Study (PHOMIC-III)

Start date: February 4, 2023
Phase: Early Phase 1
Study type: Interventional

The overarching aim of this research project is to prevent orthopedic implant-associated infections. This study aims to investigate if PDT has an effect on bacterial skin colonization in order to improve skin antisepsis strategies for the prevention of surgical site infections.

NCT ID: NCT05269134 Withdrawn - Clinical trials for Prosthetic Joint Infection

Bacteriophage Therapy in Patients With Prosthetic Joint Infections (PJI)

ACTIVE2
Start date: March 27, 2023
Phase: Phase 2
Study type: Interventional

This is a study designed to evaluate bacteriophage therapy in patients with chronic prosthetic joint infections.

NCT ID: NCT05269121 Withdrawn - Clinical trials for Bacterial Infections

Bacteriophage Therapy in First Time Chronic Prosthetic Joint Infections

ACTIVE1
Start date: September 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This study will test the feasibility of a regimen of intraoperative (IO) and intravenous (IV) PhageBank™ bacteriophage therapy in conjunction with a DAIR procedure to cure chronic prosthetic joint infection (PJI) without replacement of the prosthesis.

NCT ID: NCT05247281 Enrolling by invitation - Clinical trials for Prosthetic Joint Infection

NGS vs Culture Outcomes for Treatment of PJI

Start date: September 21, 2022
Phase: N/A
Study type: Interventional

This multicenter, randomized controlled trial will compare the use of NGS and traditional culture in directing antimicrobial treatment for patients with periprosthetic joint infection.

NCT ID: NCT05239312 Not yet recruiting - Clinical trials for Prosthetic Joint Infection

Antibiogram and Biofilm Formation of Bacteria Causing Prosthetic Joint Infections Isolated From Assiut University Hospital

Start date: March 2022
Phase:
Study type: Observational

1. Setting of antibiogram in orthopedic department 2. Evaluate the production of biofilm in bacteria isolated from specimens phenotypically and genotypically.

NCT ID: NCT05211011 Active, not recruiting - Clinical trials for Prosthetic Joint Infection

Efficacy and Safety of Intravenous Fosfomycin in Prosthetic Joint Infection

Start date: January 23, 2018
Phase: Phase 4
Study type: Interventional

The PROOF Study is an open prospective interventional non-randomized study which aim is to determine the outcome / effect and safety of fosfomycin in patients with hip, knee or shoulder PJI.

NCT ID: NCT05169229 Recruiting - Osteoarthritis, Hip Clinical Trials

Antibiotic Impregnated Bone Graft to Reduce Infection in Hip Replacement.

ABOGRAFT
Start date: April 1, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

Total hip replacement is the most successful treatment modern healthcare can offer patients to regain quality of life. Periprosthetic joint infection (PJI) is the most common and devastating complication after total hip replacement (THR). Between 0.5 to 2% of primary THR (first time hip replacement), and 8-10% of revision THR (replacement of a hip prosthesis) will become infected.1 The introduction of local antibiotics blended into bone cement has led to a reduction in postoperative infection in primary THR by half.2 Unfortunately, cement can't always be used in relevant quantities. The number of primary and revision surgeries of the hip is projected to increase dramatically. Therefore, the need for a feasible infection prophylaxis that is applicable for complex primary and revision THR in addition to antibiotics loaded cement is urgent. Impacted morselized bone allograft is often used in (revision) THR to fill bone defects. Morselized allograft has been used as a carrier for local antibiotic treatment in multiple pilot studies and appears to be an attractive and effective treatment option, both for already infected joints and as a prophylactic measure in high-risk patients (e.g. THR revision surgeries). Nonetheless, a pivotal trial to support its use in THR is lacking. The aim of this pragmatic randomized controlled double blinded drug trial is to investigate whether antibiotic impregnated bone graft (AIBG) decreases the risk of infection after hip arthroplasty compared to controls treated with placebo impregnated bone graft. Patients scheduled for elective THR will be randomized to receive AIBG or a placebo impregnated bone graft. The primary outcome variable will be the number of re-operations due to infections and PJI diagnoses 2 years postoperative.

NCT ID: NCT05060952 Recruiting - Clinical trials for Arthroplasty Complications

Calprotectin in Chronic Prosthetic Joint Infection

Start date: March 1, 2019
Phase:
Study type: Observational

A bacterial infection of an artificial joint is a serious complication that often requires additional surgery to exchange the arthroplasty. It is also difficult to recognize an infected joint, as the symptoms caused by the infection are very similar to those of other problems with arthroplasties, such as loosening of the implant. To improve the ability to diagnose prosthetic joint infections, this study compares the levels of calprotectin, a specific inflammatory protein, in the joint fluid of infected joints and joints with other complications. The underlying hypothesis is that the level of calprotectin in infected joints is significantly higher, thus facilitating the diagnosis of prosthetic joint infection.

NCT ID: NCT05000723 Recruiting - Clinical trials for Prosthetic Joint Infection

Long Term Follow-up of Patients With Prosthetic Joint Infection of the Hip Treated at University Hospitals Leuven

PROFITH
Start date: July 14, 2022
Phase:
Study type: Observational [Patient Registry]

Prosthetic Joint Infection (PJI) of a Total Hip Replacement (THR) is a disastrous complication of an otherwise extremely successful surgical procedure. It is associated with a burdensome treatment for the patient, significant challenges for the medical team and high costs for society. As more joint replacements are being performed each year, due to an ageing population and lower thresholds for surgery, the number of PJIs is on the rise. Many of these patients will be referred to University Hospitals Leuven as the physicians have extensive experience with this particular pathology and can offer a multidisciplinary and patient-tailored treatment. Many controversies exist in the field of PJI treatment, both with regard to the surgical aspects as well as the antibiotic treatment. Setting up randomized controlled trials to answer these questions has been proven to be very difficult due to large variations in patients, implants, germs, soft and hard tissues, antibiotic resistance patterns, and so on. Also, surgery for PJIs is usually non-elective / semi-urgent and therefore time to include patients into different trials is limited. Therefore the investigators will prospectively collect data on patients with PJI treated at University Hospitals Leuven, starting 01/01/2022, in order to have knowledge of own results and inform patients about chances of success prior to treatment; perform internal audits and quality checks; answer questions in the field of PJI treatment not suitable for RCTs.